Abstract
The response rate of ovarian cancer to platinum based (cisplatin and carboplatin) chemotherapies has given cause for optimism in the management of metastatic ovarian cancer, but we are still faced with the challenge that more than 50% of these patients have died within five years of diagnosis and commencing chemotherapy. Alternative second line cytotoxic therapies have not significantly influenced the survival of women with residual or relapsing metastatic ovarian cancer. What can we offer the young woman who has been treated with cisplatin or carboplatin and who is at high risk of relapse because of bulky or high grade disease at presentation or because of a persisting elevated serum CA125 antigen level?
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Mitchell, M.S. (1992) Biomodulators in cancer treatment. J. Clin. Pharmacol, 32, 2–9.
Old, L.J. (1981) Cancer immunology: the search for specificity. G.H.A. Clowes Memorial Lecture. Cancer Res., 41, 361–75.
Hakomori, S. I. (1985) Aberrant glycosylation in cancer cell membranes as focused on glyco- lipids: overview and perspectives. Cancer Res., 45, 2405–14.
Hanisch, F.G., Uhlenbruek G., Egge, H. et al. (1989) A B72.3 second-generation monoclonal antibody (CC49) defines the mucin-carried carbohydrate epitope Galβ(l-3)[NeuAcα(2–6)]GalNAc. J. Biol. Chem., 370, 21–6.
Longenecker, B.M., Willans, D.J., MacLean, G.D. et al. (1987) Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancers. J. Natl. Cancer Inst., 78,489–96.
MacLean, G.D., McEwan, A., Noujaim A.A. et al. (1991) Two novel monoclonal antibodies have potential for gynecologic cancer imaging. Antibody Immunocon. Radiopharm., 4, 297–308.
Fung, P.Y.S. and Longenecker, B.M. (1991) Specific immunosuppressive activity of epi- glycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3- HA). Cancer Res., 51,1170–6.
Fung, P.Y.S., Madej, M., Koganty, R. et al. (1990) Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res., 50, 4308–14.
MacLean, G.D. and Longenecker, B.M. (1991) Clinical significance of the Thomsen- Friedenreich antigen. Semin. Cancer Biol, 2,433–9.
Springer, G.F. (1984) T and Tn, General carcinoma autoantigens. Science, 244,1198–206.
Itzkowitz, S.H., Bloom, E.J., Kokal, W.A. et al. (1990) Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer, 66, 1960–6.
MacLean, G.D., Bowen-Yacyshyn, M.B., Samuel, J. et al. (1992) Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J. Immunother., 11,292–305.
Crum, E. (1993) Effect of cisplatin upon expression of in vivo immune tumor resistance. Cancer Immunol Immunother., 36, 18–24.
Nuti, M., Teramoto, Y.A., Mariani-Costantini, R. et al. (1982) A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int. J. Cancer, 29, 539–45.
Kobayashi, H., Terao, T., Kawashima Y. et al. (1992) Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer, J. Clin. Oncol, 10, 95–101.
Longenecker, B.M., Reddish, M., Miles, D. et al. (1993) Synthetic tumor associated sialyl- Tn antigen as an immunotherapeutic cancer vaccine. Vaccine Res., in press
MacLean, G.D., Reddish, M., Koganty, R.R. et al. (1993) Immunization of breast cancer patients using a synthetic sialyi-Tn glycocon jugate plus Detox adjuvant. Cancer Immunol Immunother 36, 215–22
Ding. L. Lalani, E., Reddish, M. et al. (1992) Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUCl gene: effect of immunization of the growth of murine mammary adenocarcinoma cells transfected with the human MUCl gene.Cancer Immunol Immunother., 36, 9–17.
De Bono, E. (1971) Practical Thinking, Penguin Book, Harmondsworth, Chapter 7.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Chapman & Hall
About this chapter
Cite this chapter
MacLean, G.D., Longenecker, B.M. (1995). Active specific immunotherapy (ASI). An immunological approach to ovarian cancer treatment. In: Sharp, F., Mason, P., Blackett, T., Berek, J. (eds) Ovarian Cancer 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-0136-4_33
Download citation
DOI: https://doi.org/10.1007/978-1-4757-0136-4_33
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-0138-8
Online ISBN: 978-1-4757-0136-4
eBook Packages: Springer Book Archive